<DOC>
	<DOCNO>NCT02344602</DOCNO>
	<brief_summary>Patients type 1 diabetes mellitus ( T1DM ) high risk develop kidney complication potentially lead end stage renal disease . Uric acid ( UA ) , end product purine metabolism , emerge important determinant renal vascular injury due ability activate renin-angiotensin-aldosterone system ( RAAS ) increase production harmful reactive oxygen specie ( ROS ) . ROS cause progressive endothelial cell dysfunction , inflammation , tissue fibrosis eventually cell death . These process enhance DM effect hyperglycemia . Since exist preventive drug therapy fail completely prevent kidney damage , examination effect UA lower initiation progression renal vascular complication therefore utmost importance . The purpose study examine effect UA lower febuxostat renal systemic vascular function patient uncomplicated T1DM . It hypothesize UA lower improve kidney systemic vascular function effect blood vessel function anti-inflammatory effect . Kidney blood vessel function assess condition normal high blood sugar level 8 week treatment UA lower drug febuxostat patient diabetes normoglycemia health control . Current treatment renal vascular complication DM patient include blockade RAAS . Unfortunately , angiotensin convert enzyme inhibitor ( ACEi ) angiotensin II ( AngII ) receptor blocker ( ARBs ) lead incomplete RAAS suppression , completely prevent renal vascular complication . Moreover , dual RAAS blockade increase renal cardiovascular risk . Recent experimental work suggest UA lower therapy block RAAS , suppress inflammation promote renal systemic vascular protection . Therefore , study critical determine possible role early UA lower renal systemic hemodynamic dysfunction young patient T1DM .</brief_summary>
	<brief_title>The Effect Uric Acid Lowering Type 1 Diabetes</brief_title>
	<detailed_description>Uric acid ( UA ) recently suggest exert deleterious effect blood pressure renal function , even baseline UA level within normal range . UA activate renin angiotensin-aldosterone system ( RAAS ) , increase oxidative stress promote inflammation . As consequence , high UA level associate metabolic abnormality ( insulin resistance , hyperglycemia ) , cardiovascular disease ( hypertension , endothelial dysfunction , arterial stiffness , cardiac diastolic dysfunction ) kidney function abnormality ( hyperfiltration - marker intraglomerular hypertension , proteinuria ) . Thus pharmacologic UA lowering may promote renal cardiovascular protection . The mechanisms underlying protective effect human , prior onset clinical disease , remain unknown . This study focus prevention complication young , normotensive type 1 diabetes mellitus ( T1DM ) patient normal renal function UA level . The study examine effect UA lower febuxostat ( FBX ) renal hemodynamic function , vascular function urinary inflammatory biomarkers . Based substantial supportive pre-clinical epidemiological data , hypothesize lower UA level within normal range baseline : 1 ) ameliorate hemodynamic abnormality characteristic T1DM , reduce renal systemic hypertensive response hyperglycemia ; 2 ) ameliorate endothelial function abnormality characteristic T1DM ; 3 ) reduce urinary inflammatory cytokines/chemokine excretion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Age 1840 year old Normoalbuminuria 24 hour urine collection Body mass index 1830 kg/m2 screen Subject able , willing perform assessment Normal electrocardiogram Normal renal ( estimate GFR &gt; 60 ml/min ) Clinic blood pressure &lt; 140/90 mmHg Type 1 DM , duration diabetes &gt; 1 year Able take medication every day Signed date write informed consent screen visit accordance GCP local legislation Hemoglobin A1c 611 % Normal uric acid level Cardiac , lung peripheral vascular disease stroke , gout Hypertension , BPlowering medicine History proliferative retinopathy Diagnosis brittle diabetes base investigator judgement Allergy either allopurinol probenecid Pregnancy , breastfeeding , reliable contraception Oral contraceptive ( due effect RAS ) Alcohol tobacco within 24 hour prior study Uric acid ≥420 μmol/L take uric acid lower agent Use agent influence GFR interfere purine metabolism ( didanosine , azothioprine , methotrexate , NSAIDs , mycophenolate ) Pancreas , pancreatic islet cell renal transplant recipient Medical history cancer treatment cancer last five year prior screen T1DM treatment drug reduce blood glucose except insulin within 6 month prior screen ( example : offlabel use metformin ) Known autonomic neuropathy proliferative retinopathy include treat proliferative retinopathy . Subjects mild nonproliferative diabetic retinopathy include Alcohol drug abuse within three month prior inform consent would interfere trial participation base investigator judgement ongoing clinical condition would jeopardize subject safety study compliance base investigator judgement ACE inhibitor , angiotensin receptor blocker , direct renin inhibitor , aldosterone antagonist Indication liver disease , define serum level either alanine transaminase ( ALT ) ( SGPT ) , aspartate transaminase ( AST ) ( SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen Blood disorder cause hemolysis unstable red blood cell ( e.g . malaria , hemolytic anemia ) Premenopausal woman ( last menstruation ≤ 1 year prior informed consent ) nursing pregnant childbearing potential practising acceptable method birth control , plan continue use method throughout study . Participation another trial investigational drug within 30 day prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Uric Acid</keyword>
	<keyword>Febuxostat</keyword>
	<keyword>Uloric</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Arterial Stiffness</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Gout Suppressants</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Free Radical Scavengers</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Angiotensin II Infusion</keyword>
	<keyword>Flow-mediated Dilation</keyword>
	<keyword>Flow-mediated Constriction</keyword>
	<keyword>Nitroglycerin</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Renin-angiotensin-aldosterone System</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>cGMP</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Renal Haemodynamic Function</keyword>
	<keyword>Inulin Clearance</keyword>
	<keyword>PAH Clearance</keyword>
	<keyword>Skin Biopsy</keyword>
	<keyword>T1R mRNA Expression</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Chemokines</keyword>
</DOC>